Oncopeptides provides new guidance on the patient recruitment in the OCEAN study and a clinical program update in a webcast at 10:00 (CET)
Stockholm – 24 April 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the company will provide an update on patient recruitment in the ongoing phase 3 study OCEAN, as well as a general update from all the company's clinical studies in a webcast at 10.00am (CET) today.Conference call for investors, analysts and the media, Wednesday, 24 April 2019, at 10 am (CET). CEO Jakob Lindberg will provide an overview of ongoing clinical studies and activities in connection with these. Phone numbers for participants from:Sweden: +46850558357Europe: +443333009030USA: